Synonym
Pamabrom, Predema; Premsyn PMS; Sunril; trade name Diurex Max
IUPAC/Chemical Name
8-bromo-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione compound with 2-amino-2-methylpropan-1-ol (1:1)
InChi Key
ATOTUUBRFJHZQG-UHFFFAOYSA-N
InChi Code
InChI=1S/C7H7BrN4O2.C4H11NO/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14;1-4(2,5)3-6/h1-2H3,(H,9,10);6H,3,5H2,1-2H3
SMILES Code
CN(C(N1C)=O)C2=C(NC(Br)=N2)C1=O.CC(C)(N)CO
Appearance
White to off-white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2933.59.5900
Biological target:
Pamabrom is a diuretic product included in retail drugs available in over-the-counter medications.
In vivo activity:
The rat paw 1% formalin test was used to assess the effects. Rats were treated with local administration of pamabrom (200-800 µg/paw) or indomethacin (200-800 µg/paw). The antinociception of pamabrom or indomethacin was evaluated with and without the local pretreatment of the blockers. Local administration of pamabrom and indomethacin produced dose-dependent antinociception during the second phase of the test. Local pretreatment of the paws with naloxone (50 µg/paw), l-nitro-arginine methyl ester (10-100 µg/paw), or 1H-(1,2,4)-oxadiazolo[4,2-a]quinoxalin-1-one (10-100 µg/paw) reverted the antinociception induced by local pamabrom, but not of indomethacin.
Reference: Can J Physiol Pharmacol. 2023 Jan 1;101(1):41-51. https://pubmed.ncbi.nlm.nih.gov/36318824/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
150.0 |
430.79 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
348.20
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
Ortiz MI, Cariño-Cortés R, Castañeda-Hernández G, Medina-Solís CE. Effect of nitric oxide-cyclic GMP-K+ channel pathway blockers, naloxone and metformin, on the antinociception induced by the diuretic pamabrom. Can J Physiol Pharmacol. 2023 Jan 1;101(1):41-51. doi: 10.1139/cjpp-2022-0277. Epub 2022 Nov 1. PMID: 36318824.
In vivo protocol:
Ortiz MI, Cariño-Cortés R, Castañeda-Hernández G, Medina-Solís CE. Effect of nitric oxide-cyclic GMP-K+ channel pathway blockers, naloxone and metformin, on the antinociception induced by the diuretic pamabrom. Can J Physiol Pharmacol. 2023 Jan 1;101(1):41-51. doi: 10.1139/cjpp-2022-0277. Epub 2022 Nov 1. PMID: 36318824.
1: Abdelaleem EA, Naguib IA, Hassan ES, Ali NW. HPTLC and RP-HPLC methods for simultaneous determination of Paracetamol and Pamabrom in presence of their potential impurities. J Pharm Biomed Anal. 2015 Oct 10;114:22-7. doi: 10.1016/j.jpba.2015.04.043. Epub 2015 May 8. PubMed PMID: 26001162.
2: Shah U, Kavad M, Raval M. Development and Validation of Stability-indicating RP-HPLC Method for Estimation of Pamabrom in Tablets. Indian J Pharm Sci. 2014 May;76(3):198-202. PubMed PMID: 25035530; PubMed Central PMCID: PMC4090826.
3: Tan DS, Sklar GE. Erythema multiforme secondary to dimenhydrinate in a patient with previous similar reactions to pamabrom. Ann Pharmacother. 2014 Mar;48(3):425-8. doi: 10.1177/1060028013518728. Epub 2014 Jan 6. PubMed PMID: 24396093.
4: El-Houssini OM. RP-LC and TLC Densitometric Determination of Paracetamol and Pamabrom in Presence of Hazardous Impurity of Paracetamol and Application to Pharmaceuticals. Anal Chem Insights. 2013 Sep 5;8:73-81. doi: 10.4137/ACI.S12349. eCollection 2013. PubMed PMID: 24046511; PubMed Central PMCID: PMC3771670.
5: Lee S, Yang Y, Fishman D, Banaszak Holl MM, Hong S. Epithelial-mesenchymal transition enhances nanoscale actin filament dynamics of ovarian cancer cells. J Phys Chem B. 2013 Aug 8;117(31):9233-40. doi: 10.1021/jp4055186. Epub 2013 Jul 26. PubMed PMID: 23848376; PubMed Central PMCID: PMC3784653.
6: Ortiz MI. Primary dysmenorrhea among Mexican university students: prevalence, impact and treatment. Eur J Obstet Gynecol Reprod Biol. 2010 Sep;152(1):73-7. doi: 10.1016/j.ejogrb.2010.04.015. Epub 2010 May 15. PubMed PMID: 20478651.
7: Ortiz MI, Rangel-Flores E, Carrillo-Alarcón LC, Veras-Godoy HA. Prevalence and impact of primary dysmenorrhea among Mexican high school students. Int J Gynaecol Obstet. 2009 Dec;107(3):240-3. doi: 10.1016/j.ijgo.2009.07.031. Epub 2009 Aug 27. PubMed PMID: 19716130.
8: Min JA, Kim HS, Kim HO, Park YM. Fixed drug eruption caused by pamabrom. Clin Exp Dermatol. 2009 Oct;34(7):e455-6. doi: 10.1111/j.1365-2230.2009.03501.x. Epub 2009 Aug 14. PubMed PMID: 19681920.
9: Ortiz MI, Fernández-Martínez E, Pérez-Hernández N, Macías A, Rangel-Flores E, Ponce-Monter H. Patterns of prescription and self-medication for treating primary dysmenorrhea in a Mexican population. Proc West Pharmacol Soc. 2007;50:165-7. PubMed PMID: 18605257.
10: Swanson JK, English JC 3rd. Serum sickness-like reaction to Pamabrom. J Drugs Dermatol. 2006 Mar;5(3):284-6. PubMed PMID: 16573265.
11: Di Girolamo G, Sánchez AJ, De Los Santos AR, González CD. Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea? Expert Opin Pharmacother. 2004 Mar;5(3):561-70. Review. PubMed PMID: 15013925.
12: Kauppinen K. Fixed drug eruptions and oral rechallenge. Cleve Clin J Med. 1991 Jan-Feb;58(1):64-5. PubMed PMID: 1829986.
13: Nedorost S, Taylor JS, Camisa C, Tomecki KJ, Helm T, Durkin WJ. Fixed drug eruption from pamabrom. Cleve Clin J Med. 1991 Jan-Feb;58(1):33-4. PubMed PMID: 1829985.
14: IANIUK VS. [The use of syncol in surgical practice]. Probl Gematol Pereliv Krovi. 1960 Aug;5:61-2. Russian. PubMed PMID: 13717260.
15: DOHERTY JE, BEARD OW. A study of diuretic action of pamabrom (2-amino-2-methyl-propanol-1-8-bromotheophylline) in cardiac failure. Am Heart J. 1953 Aug;46(2):288-90. PubMed PMID: 13080166.
